AbbVie Inc. took a little shot at the Trump administration’s trade policy, as the drugmaker said Friday that rather than tariffs, tax reform is the key to boosting U.S. manufacturing. The ...

If consummated, the marriage will also give AbbVie access to Aliada's MODEL platform for delivering large-molecule drugs across the blood-brain barrier (BBB). The Boston biotech said the platform ...

However, AbbVie also paid dividends during these 10 years. Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — you can become an ...

AbbVie Inc. raised its profit outlook for the year on better-than-expected sales from newer autoimmune treatments, but warned its forecast doesn’t take into account any potential changes in ...

AbbVie is poised to grow this year for the first time since Humira's U.S. patent expired. The dividend yields a generous 3.7% and features decades of consistent growth. While tariffs, politics ...

AbbVie Inc.’s (NYSE:ABBV) year is off to a very strong start. The company beat Q1 2025 revenue and EPS estimates and raised the full-year EPS guidance range by $0.10 and the full-year revenue ...

AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year ...